Uloric® (febuxostat) is a medication manufactured by Takeda Pharmaceuticals that is prescribed to treat a type of arthritis called gout in adults. Gout happens when a naturally occurring substance in the body called uric acid builds up and causes sudden attacks of redness, swelling, and pain in one or more joints.
On 2/21/19, the U.S. Food and Drug Administration (FDA) concluded that there is an increased risk of death with Uloric compared to another gout medicine, allopurinol. The FDA reported that this conclusion was based on its in-depth review of results from a safety clinical trial that found an increased risk of heart-related death and death from all causes with Uloric. As a result, the FDA updated the Uloric prescribing information to require a Boxed Warning, its most prominent and serious warning, and a new patient Medication Guide. The FDA also limited the approved use of Uloric to certain patients who are not treated effectively or experience severe side effects with allopurinol.
Unfortunately, this warning comes too late for some users who have suffered fatal or non-fatal heart attacks or strokes over the last ten years since the drug was approved in 2009. The emerging Uloric litigation claims that the manufacturer, Takeda Pharmaceuticals, failed to warn users of the increase risk of heart-related or other types of deaths.
How We Can Help:
If you or someone you love has suffered any of the following types of medical events while taking Uloric®, you should be aware of the emerging litigation.
- Heart-related death
- Heart attack
- Unstable angina with Urgent Coronary Revascularization
Attorney Pamela A. Borgess, the founder of Borgess Law, LLC, has extensive experience with numerous national high-profile defective medical drug/device cases and can discuss your legal options. For more information about the Uloric litigation or to discuss a potential claim, contact Borgess Law at (567) 455-5955. You can also contact Borgess Law by submitting an online inquiry. Borgess Law never charges for initial consultations. We welcome any questions you may have.